February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
5 citations
,
August 2018 in “Neurology and Therapy” Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
1 citations
,
August 2023 in “Acta dermato-venereologica” Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.
November 2025 in “Frontiers in Pharmacology” 64 drugs can cause hair loss, needing better monitoring and updated labels.
September 2025 in “Journal of Dermatology Research” Sebamed® shampoo effectively reduces hair loss and promotes hair growth.
2 citations
,
May 2024 in “The World Journal of Men s Health” Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
27 citations
,
August 2024 in “Frontiers in Pharmacology” Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.
1 citations
,
September 2025 in “PLoS ONE” Certain drugs may cause vitiligo, so patients should be monitored.
January 2026 in “Frontiers in Pharmacology” Certain drugs can cause male infertility, so fertility counseling and sperm preservation are advised.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
6 citations
,
July 2022 in “Journal of health economics and outcomes research” Adolescents with severe alopecia incur significantly higher healthcare costs.
3 citations
,
February 2024 in “arXiv (Cornell University)” Google Search ads effectively gathered a diverse dermatology image dataset for research and AI development.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
2 citations
,
October 2024 in “Dermatology and Therapy” Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
Finasteride can cause long-term side effects like sexual dysfunction and depression.
Baricitinib shows promise for treating alopecia areata with mild side effects.
1 citations
,
October 2025 in “Frontiers in Immunology” Avacopan is generally safe, with some minor side effects like nausea and fatigue.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
2 citations
,
October 2023 in “Dermatology and therapy” Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
February 2024 in “medRxiv (Cold Spring Harbor Laboratory)” The study aims to understand how mood, physical activity, light exposure, and seasonal changes affect sleep patterns.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.